• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗菌药物耐药性研究中对照组选择的重要性:以铜绿假单胞菌、肠球菌和大肠杆菌为例

Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli.

作者信息

Harris Anthony D, Samore Matthew H, Lipsitch Marc, Kaye Keith S, Perencevich Eli, Carmeli Yehuda

机构信息

Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, and VA Maryland Health Care System, Baltimore, MD, USA.

出版信息

Clin Infect Dis. 2002 Jun 15;34(12):1558-63. doi: 10.1086/340533. Epub 2002 May 23.

DOI:10.1086/340533
PMID:12032889
Abstract

We aimed to illustrate the importance of control-group selection on the results of risk factor analysis for (1) imipenem-resistant Pseudomonas aeruginosa, (2) vancomycin-resistant enterococci (VRE), and (3) ampicillin-sulbactam-resistant Escherichia coli. Case patients were compared with 2 different control groups: patients with the susceptible form of the organism (type 1), and control patients among whom the case patients arose during the same period as the case patients (type 2). Comparison of case patients who had imipenem-resistant P. aeruginosa with type-1 control patients identified use of imipenem (odds ratio [OR], 27.1) and quinolones (OR, 3.25) as a risk factor for selection of antimicrobial resistance, and comparison of the same case patients with type-2 control patients identified imipenem (OR, 6.34). When case patients with VRE were compared with type-1 and with type-2 control patients, use of vancomycin was identified as a risk factor (OR, 4.38 and 2.77, respectively). Comparison of case patients who had ampicillin-sulbactam-resistant E. coli compared with type-1 control patients identified ampicillin-sulbactam (OR, 2.71) and quinolones (OR, 2.72), and comparison with type-2 control patients identified ampicillin-sulbactam (OR, 1.68). The selection of control patients from the potentially suboptimal control type 1 can falsely identify certain antibiotics and overestimate the OR of the resistance-defining antibiotic.

摘要

我们旨在阐明对照组选择对以下三种情况的危险因素分析结果的重要性

(1)耐亚胺培南铜绿假单胞菌、(2)耐万古霉素肠球菌(VRE)和(3)耐氨苄西林 - 舒巴坦大肠杆菌。将病例患者与2个不同的对照组进行比较:感染该病原体敏感型的患者(1型),以及与病例患者在同一时期出现的对照患者(2型)。耐亚胺培南铜绿假单胞菌的病例患者与1型对照患者比较,确定亚胺培南的使用(比值比[OR],27.1)和喹诺酮类药物(OR,3.25)是抗菌药物耐药性选择的危险因素,而相同病例患者与2型对照患者比较,确定亚胺培南(OR,6.34)。当VRE病例患者与1型和2型对照患者比较时,万古霉素的使用被确定为危险因素(分别为OR,4.38和2.77)。耐氨苄西林 - 舒巴坦大肠杆菌的病例患者与1型对照患者比较,确定氨苄西林 - 舒巴坦(OR,2.71)和喹诺酮类药物(OR,2.72),与2型对照患者比较,确定氨苄西林 - 舒巴坦(OR,1.68)。从潜在不太理想的1型对照中选择对照患者可能会错误地识别某些抗生素,并高估定义耐药性的抗生素的OR。

相似文献

1
Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli.抗菌药物耐药性研究中对照组选择的重要性:以铜绿假单胞菌、肠球菌和大肠杆菌为例
Clin Infect Dis. 2002 Jun 15;34(12):1558-63. doi: 10.1086/340533. Epub 2002 May 23.
2
Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients.住院患者中耐亚胺培南铜绿假单胞菌的危险因素
Clin Infect Dis. 2002 Feb 1;34(3):340-5. doi: 10.1086/338237. Epub 2001 Dec 26.
3
Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients.耐亚胺培南铜绿假单胞菌的危险因素:两项住院患者病例对照研究的比较分析
J Hosp Infect. 2005 Feb;59(2):96-101. doi: 10.1016/j.jhin.2004.09.007.
4
[A case-control study on the risk factors of nosocomial infection caused by imipenem-resistant Pseudomonas aeruginosa].[耐亚胺培南铜绿假单胞菌医院感染危险因素的病例对照研究]
Zhonghua Liu Xing Bing Xue Za Zhi. 2005 Jul;26(7):511-4.
5
The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit.烧伤病房中获得耐亚胺培南铜绿假单胞菌的危险因素。
Burns. 2005 Nov;31(7):870-3. doi: 10.1016/j.burns.2005.04.015. Epub 2005 Jun 21.
6
[Analysis of drug resistance spectrum and its mechanism in 1017 clinical bacterial isolates].
Di Yi Jun Yi Da Xue Xue Bao. 2005 Dec;25(12):1529-32, 1545.
7
Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity.重症监护病房患者多重耐药铜绿假单胞菌的获得:具有抗铜绿假单胞菌活性抗生素的作用
Clin Infect Dis. 2004 Mar 1;38(5):670-7. doi: 10.1086/381550. Epub 2004 Feb 17.
8
Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms.重症患者医院获得性肺炎:与耐亚胺培南菌所致感染相关的因素
Infection. 2005 Jun;33(3):129-35. doi: 10.1007/s15010-005-4021-8.
9
Low antibiotic resistance rates in Staphylococcus aureus, Escherichia coli and Klebsiella spp but not in Enterobacter spp and Pseudomonas aeruginosa: a prospective observational study in 14 Swedish ICUs over a 5-year period.金黄色葡萄球菌、大肠杆菌和克雷伯菌属的抗生素耐药率较低,但肠杆菌属和铜绿假单胞菌并非如此:一项对瑞典14个重症监护病房进行的为期5年的前瞻性观察研究。
Acta Anaesthesiol Scand. 2007 Aug;51(7):937-41. doi: 10.1111/j.1399-6576.2007.01364.x.
10
[Distribution and drug-resistance of 3 500 gram-negative bacteria in Guangzhou].广州3500株革兰阴性菌的分布及耐药性
Di Yi Jun Yi Da Xue Xue Bao. 2005 Feb;25(2):132-8.

引用本文的文献

1
Phylogenetic context of antibiotic resistance provides insights into the dynamics of resistance emergence and spread.抗生素耐药性的系统发育背景为耐药性的出现和传播动态提供了见解。
medRxiv. 2025 Jun 5:2025.06.04.25328982. doi: 10.1101/2025.06.04.25328982.
2
Carbapenem-resistant Klebsiella pneumoniae: Risk Factors for Isolation Among Hospitalized Patients.耐碳青霉烯类肺炎克雷伯菌:住院患者中分离出该菌的危险因素
Brown J Hosp Med. 2022 Dec 16;2(1):57568. doi: 10.56305/001c.57568. eCollection 2023.
3
Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study.
碳青霉烯类耐药肠杆菌科血流感染的危险因素:一项巢式病例对照对照研究。
J Antimicrob Chemother. 2024 Sep 3;79(9):2132-2141. doi: 10.1093/jac/dkae157.
4
The Next Generation: Mentoring and Diversity in the Antibacterial Resistance Leadership Group.下一代:抗菌耐药性领导组织中的指导和多样性。
Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S331-S335. doi: 10.1093/cid/ciad532.
5
Can precision antibiotic prescribing help prevent the spread of carbapenem-resistant organisms in the hospital setting?精准使用抗生素能否有助于预防碳青霉烯类耐药菌在医院环境中的传播?
JAC Antimicrob Resist. 2023 Mar 29;5(2):dlad036. doi: 10.1093/jacamr/dlad036. eCollection 2023 Apr.
6
Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA).耐碳青霉烯类肠杆菌科细菌感染的危险因素:一项国际配对病例对照研究(EURECA)
EClinicalMedicine. 2023 Feb 27;57:101871. doi: 10.1016/j.eclinm.2023.101871. eCollection 2023 Mar.
7
Case-case-control study of risk factors for carbapenem-resistant Enterobacterales infections among hospitalized patients.住院患者中耐碳青霉烯类肠杆菌科细菌感染危险因素的病例-病例对照研究
Antimicrob Steward Healthc Epidemiol. 2022 Jul 14;2(1):e118. doi: 10.1017/ash.2022.244. eCollection 2022.
8
A case-control study of infections caused by producing New Delhi metallo-beta-lactamase-1: Predictors and outcomes.产新德里金属β-内酰胺酶-1 所致感染的病例对照研究:预测因素和结局。
Front Cell Infect Microbiol. 2022 Jul 28;12:867347. doi: 10.3389/fcimb.2022.867347. eCollection 2022.
9
Weighted nearest neighbours-based control group selection method for observational studies.基于加权最近邻的观察性研究对照组选择方法。
PLoS One. 2020 Jul 23;15(7):e0236531. doi: 10.1371/journal.pone.0236531. eCollection 2020.
10
Characteristics and Clinical Outcomes of Extended-Spectrum beta-lactamase-producing Bacteremia in Cancer Patients.癌症患者产超广谱β-内酰胺酶菌血症的特征及临床结局
Infect Chemother. 2020 Mar;52(1):59-69. doi: 10.3947/ic.2020.52.1.59.